- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dapagliflozin: A Review in Type 1 Diabetes ; volume:79 ; number:17 ; day:29 ; month:10 ; year:2019 ; pages:1877-1884 ; date:11.2019
Drugs ; 79, Heft 17 (29.10.2019), 1877-1884, 11.2019
- Urheber
-
Paik, Julia
Blair, Hannah A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-019-01213-x
- URN
-
urn:nbn:de:101:1-2020032301203828396981
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Paik, Julia
- Blair, Hannah A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
Correction to: Dapagliflozin: A Review in Type 1 Diabetes
Correction to: Dapagliflozin: A Review in Type 2 Diabetes
P62 Dapagliflozin Preserves Renal Vasodilating Capacity in Hypertensive Patients with Type 2 Diabetes
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Dapagliflozin
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure
Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
Typ-2-Diabetes – Dapagliflozin: Erfahrungen mit einer neuen Wirkstoffklasse
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment